United Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from Bank of America Securities reiterated a Hold rating on the stock and has a $626.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jason Gerberry has given his Hold rating due to a combination of factors, balancing strong clinical momentum with valuation and execution risks. The positive Phase 3 TETON‑1 data materially increase the likelihood that Tyvaso will secure an additional IPF indication, supporting a higher peak sales outlook of roughly $4 billion and justifying a higher price objective of $626.
At the same time, he sees the risk/reward as balanced, as the current share price already reflects much of this upside and the IPF opportunity still carries adherence and tolerability questions. Discontinuation and cough rates observed in prior studies, along with the practical burden of four-times-daily nebulization, could temper real‑world uptake, leading him to maintain a Neutral stance despite raising his estimates and target.
In another report released on March 23, Wells Fargo also maintained a Hold rating on the stock with a $486.00 price target.
Based on the recent corporate insider activity of 301 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.